Transdermal adhesive compositions, devices, and methods

A method of delivering at least one pharmaceutically active compound to a subject, the method comprising contacting a transdermal adhesive composition with the subject, wherein the transdermal adhesive composition comprises

• an adhesive comprising washed polymerization reaction product of at least two ethylenically unsaturated monomers;
• (S)—N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate or a pharmaceutically acceptable salt thereof;
• wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive;
• and
• wherein the composition is essentially free of any added antioxidant.

A method of delivering at least one pharmaceutically active agent to a subject, the method comprising contacting the subject with a transdermal drug delivery device comprising:

• a transdermal adhesive composition comprising:
• an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers;
• and
• at least one pharmaceutically active compound which is susceptible to oxidative degradation;
• wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive;
• a backing sheet coated with the transdermal adhesive composition, wherein the transdermal adhesive composition coating covers at least a portion of a major surface of the backing sheet;
• and
• wherein the composition is essentially free of any added antioxidant.

A method of making a transdermal adhesive composition, the method comprising:

• washing the polymerization reaction product of at least two ethylenically unsaturated monomers to form a washed polymerization reaction product and admixing the washed polymerization reaction product with at least one pharmaceutically active compound which is susceptible to oxidative degradation;
• wherein the transdermal adhesive composition comprises:
• the adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers;
• and
• the least one pharmaceutically active compound which is susceptible to oxidative degradation;
• wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive;
• wherein any free radical initiator, if present in the adhesive, is present at a level of less than 20 ppm, based upon the total weight of the adhesive;
• and
• wherein the composition is essentially free of any added antioxidant.